logo
Experts issue warning over worsening crisis threatening food security around the globe: 'A threat to humanity'

Experts issue warning over worsening crisis threatening food security around the globe: 'A threat to humanity'

Yahoo21-07-2025
Experts issue warning over worsening crisis threatening food security around the globe: 'A threat to humanity'
One of the biggest consequences of rising global temperatures is the impact they have on food security. Across the globe, rising temperatures are threatening agricultural production, causing experts to sound the alarm, as was the case at a recent gathering held in Kathmandu, Nepal.
What's happening?
Key stakeholders at the Sagarmatha Sambaad forum in May discussed the challenges of Earth's overheating, underscoring the reality of food and water insecurity.
According to reporting by Republica, one of the topics discussed was the current water crisis, which Dr. Mark Smith, executive director of the International Water Management Institute, said poses a "serious threat to the long-term sustainability for future generations but also to equality."
"Scientists have considered this a threat to humanity," Smith added.
With extreme weather — such as intense droughts and increasingly powerful storms — destroying crops and driving food prices up, vulnerable areas are grappling with climate-driven poverty and starvation.
Leaders from around the world emphasized the need to take action and develop solutions to address all aspects of the current crisis.
Why is global food insecurity important?
Rising global temperatures are taking a serious toll on farmers trying to make a living and yield successful harvests. With intense droughts and more powerful storms ruining crops, farmers have increased their prices, which in turn makes everyday necessities less affordable and accessible.
Global food insecurity not only threatens public health but also human rights. As vulnerable communities suffer from the consequences of extreme weather, they lose access to safe and nutritious food and water supplies.
What's being done about climate-driven food insecurity?
World leaders and organizations are advocating for climate-driven solutions to combat food insecurity and water shortages. However, these conversations are just the beginning. Experts have indicated that more steps need to be taken to practically tackle these global challenges on a larger scale.
As Republica reported, Dr. Usha Jha, a former member of Nepal's National Planning Commission, warned at the forum that hunger and poverty could rise if precautions aren't taken.
Do you worry about how much food you throw away?
Definitely
Sometimes
Not really
Never
Click your choice to see results and speak your mind.
Ken Shimizu, the Food and Agriculture Organization Country Representative for Nepal and Bhutan, raised another important point of discussion, noting how the climate crisis has brought on numerous socioeconomic challenges.
"It is a further challenge to ease access to necessary financing, technology, and support," Shimizu said, per Republica.
Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics
Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics

Associated Press

time22 minutes ago

  • Associated Press

Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics

Olympus Co-founds Swan EndoSurgical With Revival Healthcare Capital TOKYO - July 28, 2025 ( NEWMEDIAWIRE ) - Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer, and more fulfilling, today announced the conclusion of an agreement with Revival Healthcare Capital (Revival) to drive advancements in endoluminal robotics. Olympus and Revival will co-found Swan EndoSurgical, a new company dedicated to developing a novel robotic system designed to revolutionize gastrointestinal (GI) patient care in the future. Endoluminal robotics aims to empower more physicians to safely perform innovative techniques, enhancing patient access to treatment options that support safety and improved recovery times. This groundbreaking advancement has the potential to create new and significantly enhanced minimally invasive treatment options for major unmet medical needs by boosting precision and efficiency in procedures addressing ergonomic strain for healthcare professionals. Bob White, Representative Executive Officer, President and Chief Executive Officer at Olympus, commented, 'This partnership marks a significant milestone in our strategic initiative to advance endoluminal robotics. We are excited to enter this collaboration that we expect to play a pivotal role in reshaping the GI market by expanding procedural capabilities for physicians. This will allow the delivery of transformative, organ-sparing care that enhances outcomes for a broad patient population.' For decades, endoscopy - placing a flexible camera into an existing body orifice - has yielded early and accurate diagnoses of conditions such as GI tract cancer. In recent years, specialists, primarily gastroenterologists, have begun performing endoscopic therapeutic procedures, such as cancer resection, by inserting instruments through the endoscope. However, manual endoscopes and their instruments have limitations that make many advanced procedures within the lumen of the GI tract challenging and not widely available globally. The development of an endoluminal robot, with its ability to easily maneuver within the GI tract and deploy flexible arms, provides the opportunity for more patients to benefit from safe and effective procedures, potentially avoiding invasive surgery. This innovation allows for the early, safe, and effective treatment of lesions or tumors in the GI tract relative to current therapeutic options. Furthermore, the technology has the potential for application in numerous other disease areas. Headquartered in the United States, Swan EndoSurgical has assembled a leadership team of highly experienced industry professionals who will drive technical, clinical, and commercial development of the robotic platform. About Swan EndoSurgical Swan EndoSurgical, Inc. is an innovative start-up co-founded by Revival Healthcare Capital and Olympus that is focused on the development of endoluminal surgical robotics with the aim to create effective treatment of lesions or tumors in the GI tract relative to current therapeutic options. For additional information, visit the Company's website at or contact [email protected]. About Revival Healthcare Capital Revival Healthcare Capital is an investment firm focused on the MedTech sector. Revival specializes in transformative external innovation partnerships and other opportunities where its team of experienced operators and investors believes it can provide leadership, resources, and deep sector insights - beyond its capital - to further support companies' growth strategies. For additional information, visit Revival's website at or contact [email protected] . About Olympus At Olympus, we are committed to Our Purpose of making people's lives healthier, safer, and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis, and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit and follow our global X account: @Olympus_Corp. Media contact: Mail: [email protected] Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS]

Ex Vivo Drug Response Platform From KYAN Shows Clinical Utility in Non-Hodgkin Lymphoma Patients
Ex Vivo Drug Response Platform From KYAN Shows Clinical Utility in Non-Hodgkin Lymphoma Patients

Associated Press

time22 minutes ago

  • Associated Press

Ex Vivo Drug Response Platform From KYAN Shows Clinical Utility in Non-Hodgkin Lymphoma Patients

accurately predicted response in prospective cohort; results published in JCO Precision Oncology, a journal of ASCO SINGAPORE, July 28, 2025 / / -- A prospective clinical study published in JCO Precision Oncology, a journal of the American Society of Clinical Oncology (ASCO), confirms that KYAN Technologies' platform (Quadratic Phenotypic Optimization Platform, or QPOP) accurately predicts clinical response in relapsed/refractory non-Hodgkin lymphoma (R/R-NHL), including hard-to-treat subtypes where genomic testing often offers limited guidance. This prospective clinical validation study, conducted in 117 patients across two tertiary cancer centers, represents the largest published cohort to date using an ex vivo functional precision medicine platform in lymphoma. The results demonstrated meaningful clinical utility, reporting both objective response rates (ORR) and Kaplan-Meier survival outcomes, with significantly longer progression-free survival (PFS) in patients treated with combinations prioritized by the platform. The study showed that functionally guided therapies delivered not just predictive concordance, but measurable clinical benefit in a real-world setting. Key study findings: • 74.5 percent test accuracy in predicting clinical response • 59 percent ORR in patients treated with platform-guided combinations • Three-fold improvement in PFS compared to prior treatment line • Two-year survival analysis showed a statistically significant benefit over salvage therapy (P = 0.0191) 'This study reinforces the scientific rigor behind the platform by showing we can deliver reproducible, clinically concordant results across a large cohort of real patient samples,' said Edward K. Chow, PhD, KYAN Technologies' Chief Scientific Officer. 'We're especially grateful to the essential contributions of our clinical collaborators at the National University of Singapore (NUS), National University Hospital (NUH), and Singapore General Hospital (SGH). Their guidance, insights and commitment helped shape a platform that delivers timely, reliable, and actionable guidance for both physicians and patients.' directly measures how live tumor cells respond to therapy. Using a proprietary experimental design, the platform tests hundreds of clinically relevant drug treatments at once, including standard-of-care regimens, off-label therapies with known safety profiles, and novel options, and ranks them based on predicted treatment response. This functional, patient-specific readout provides oncologists with real-time guidance tailored to the biology of each tumor. 'This study marks a defining milestone in journey toward clinical adoption. With our clinical and analytical validation now published in a peer-reviewed journal, we're positioned to scale the platform in the U.S., starting with CLIA deployment and expanding through partnerships with leading clinicians and institutions,' said Hugo Saavedra, Chief Executive Officer of KYAN Technologies. The results underscore the broader potential of functional precision medicine to inform treatment decisions and combination design across oncology. By capturing how each patient's tumor responds to a breadth of drug regimens, not only guides clinical care but also offers insights that can support off-label strategy, clinical trial selection, and future drug development. About KYAN Technologies KYAN Technologies is a functional precision oncology company accelerating the discovery and deployment of effective cancer treatments. Its proprietary platform, uses ex vivo testing and combinatorial analytics to generate phenotypic response data from patient-derived tumor samples. This approach provides a clinically actionable layer of insight that complements genomic and transcriptomic tools. supports both patient care and drug development, helping clinicians identify tailored treatment options and enabling biopharma partners to prioritize combination strategies, select indications, and design smarter trials. Headquartered in Singapore, KYAN is expanding its U.S. presence to advance clinical deployment and strategic collaborations across oncology research and care. For media inquiries contact: Sudha Sruthi, Corporate Development email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

Associated Press

time22 minutes ago

  • Associated Press

NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

HONG KONG, July 28, 2025 /PRNewswire/ -- Akeso, Inc. ( ('Akeso' or the 'Company') is pleased to announce that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ivonescimab (PD-1/VEGF bispecific antibody) in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). This submission represents the third accepted application for ivonescimab in China, following previous filings for its combination therapy in EGFR-TKI resistant locally advanced or metastatic non-squamous NSCLC (nsq-NSCLC), as well as its monotherapy for first-line treatment of PD-L1 positive advanced NSCLC. PD-1 combined with chemotherapy has become a cornerstone in cancer therapy. The sNDA for ivonescimab's new indication is based on the strong positive outcomes from its Phase III trial (AK112-306/HARMONi-6 study), which showed that ivonescimab combined with chemotherapy is superior to tislelizumab plus chemotherapy. Building on the success of its head-to-head comparison with pembrolizumab, ivonescimab's ability to outperform PD-1 combination therapy marks a significant step forward in the evolution of global cancer immunotherapy. Currently, ivonescimab is involved in over 12 registrational/Phase III clinical trials worldwide, including six head-to-head studies with PD-1/L1 inhibitors. These trials span a diverse range of malignancies, such as various subtypes of lung cancer, first-line colorectal cancer, first-line head and neck squamous cell carcinoma, first-line biliary tract cancer, first-line pancreatic cancer, and first-line triple-negative breast cancer, among others. Ivonescimab has established a broad and strategic footprint across key cancer immunotherapy indications. As part of the company's 'IO+ADC' 2.0 oncology strategy, ivonescimab is positioned as a cornerstone agent in immuno-oncology, being evaluated in combination with innovative therapies targeting novel mechanisms and pathways. Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. ( 'Akeso') contains 'forward-looking statements'. These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. About Akeso Akeso (HKEX: is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 2 new drugs with 2 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit and follow us on Linkedin. View original content: SOURCE Akeso, Inc.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store